[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

90

1 Now, clearly, the issue also is whether we
2 should aim, our goals should be protection against
3 infection or protection against disease. It's a
4 slightly different question than the first.
5 I believe this is one that has not
6 received enough attention either. Lip service has
7 been made to it, but, certainly, a more detailed
8 analysis of this question is necessary.
9 The one issue that is before us today
10 obviously is the other critical element. Can
11 vaccination after exposure in any way bring benefit in
12 terms of delaying disease or, hopefully, impacting
13 also on transmission?
14 Next slide, please. Variation is an
15 issue, obviously important for this virus. I would
16 say that the key issue here that we need to grapple
17 with is: What is the relationship between sequence
18 variation that many people are involved in putting on
19 the table now and the questions of antigenic
20 variation, the questions of biologic variation, and
21 eventually also the pathogenic subtype that exists in
22 these viruses?
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]